Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

17.1%

6 terminated/withdrawn out of 35 trials

Success Rate

80.6%

-5.9% vs industry average

Late-Stage Pipeline

20%

7 trials in Phase 3/4

Results Transparency

44%

11 of 25 completed trials have results

Key Signals

2 recruiting11 with results

Enrollment Performance

Analytics

Phase 1
20(58.8%)
Phase 2
7(20.6%)
Phase 3
7(20.6%)
34Total
Phase 1(20)
Phase 2(7)
Phase 3(7)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (35)

Showing 20 of 35 trials
NCT07517315Unknown

Expanded Access to Vodobatinib for Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Not Responded to Previous Treatments

Role: lead

NCT07042100Phase 1Recruiting

A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.

Role: lead

NCT03655236Phase 2Terminated

PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706

Role: lead

NCT02629692Phase 1Active Not Recruiting

Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

Role: lead

NCT04942054Phase 1Terminated

A Study in Patients With Advanced Breast Cancer

Role: lead

NCT04242953Phase 1Completed

Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in Healthy Male and Post-menopausal Female Subjects

Role: lead

NCT03996460Phase 2Recruiting

K0706 for Patients Diagnosed With Dementia With Lewy Bodies

Role: collaborator

NCT03450629Phase 3Completed

Evaluation of Safety and Efficacy of PDP-716

Role: lead

NCT03055143Phase 1Completed

Study of Doxorubicin in Patients With Metastatic Breast Cancer/Advanced Ovarian Cancer

Role: lead

NCT03426267Phase 3Completed

Evaluation of Efficacy and Safety of SDN-037

Role: lead

NCT00945958Phase 3Completed

Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension

Role: lead

NCT00947661Phase 3Completed

Efficacy and Safety of SPARC0912 and Reference0912 in Open Angle Glaucoma or Ocular Hypertension

Role: lead

NCT02597465Phase 3Withdrawn

A Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507

Role: lead

NCT04332549Phase 1Withdrawn

To Assess the Bioavailability and Safety of Paclitaxel Injection Concentrate for Suspension in Subjects With Locally Recurrent or Metastatic Breast Cancer

Role: lead

NCT02970019Phase 1Completed

Safety and Tolerability Study of K0706 in Subjects With Parkinson's Disease

Role: lead

NCT03445338Phase 1Completed

To Evaluate the Safety, Tolerability and Pharmacokinetics of K0706 in Plasma and Cerebrospinal Fluid in Healthy Volunteers

Role: lead

NCT01457352Phase 3Completed

Efficacy and Safety of SPARC0921 in Subjects With Spasticity

Role: lead

NCT03316820Phase 1Completed

Bioavailability Study of K0706 in Healthy Subjects

Role: lead

NCT02991222Phase 1Completed

Bioavailability Study of SPARC001(Study 1) in Healthy Adult Volunteers

Role: lead

NCT02887534Phase 2Withdrawn

Evaluation of Efficacy and Safety of SPARC1401 in Acute Low Back Pain

Role: lead